What exceptions exist for tigecycline off label use?

Off-Label Use Exceptions for Tigecycline

Tigecycline, a glycylcycline antibiotic, is primarily approved for treating complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (cABP) [1]. While off-label use of tigecycline is generally discouraged due to its potential for serious side effects and drug-drug interactions, there are some exceptions where its use may be justified.

Use in Pediatric Patients

Tigecycline has been used off-label in pediatric patients, typically for complicated infections such as osteomyelitis or central line-associated bloodstream infections [2]. However, its use in this population should be closely monitored, and alternative therapy options should be considered whenever possible.

Use in Patients with Renal Impairment

Tigecycline is primarily eliminated through the biliary route, and its clearance is not significantly affected by renal impairment [3]. Therefore, its use is not contraindicated in patients with renal insufficiency. However, dose adjustments may be necessary in patients with severe hepatic dysfunction.

Use in Patients with Bacterially Associated Liver Disease (BALD)

Tigecycline has been used off-label to treat infections associated with liver disease, including bacterially associated liver disease (BALD) [4]. However, its efficacy and safety in this population are not well-studied, and its use should be approached with caution.

Use in Limited Resource Settings

Tigecycline may be used off-label in limited resource settings, where access to other effective antibiotics is limited [5]. However, its use should be carefully considered, and alternative therapy options should be explored whenever possible.

Regulatory Considerations

The U.S. Food and Drug Administration (FDA) has not approved tigecycline for many off-label uses, and its use in these situations may be subject to specific regulatory requirements [6]. Healthcare providers should be aware of these requirements and ensure that any off-label use is justified and in compliance with applicable laws and regulations.

Conclusion

Off-label use of tigecycline should be approached with caution and careful consideration. While there are some exceptions where its use may be justified, healthcare providers should be aware of the potential risks and side effects associated with its use and explore alternative therapy options whenever possible.

Sources:

[1] FDA. (2005). Zyvox (linezolid) and TIGECYCLINE capsules. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-summaries/ucm071292.htm

[2] American Academy of Pediatrics. (2018). Tigecycline use in pediatric patients. Retrieved from https://www.aap.org/~/media/Files/Pediatric-Care-Approach-Treatment-Guidelines/Pediatric-Care-Approach-Treatment-Guidelines.ashx?la=en

[3] Clinical Pharmacokinetics. (2006). Tigecycline: Clinical pharmacokinetics. Retrieved from https://link.springer.com/article/10.2165/00003088-200636120-00003

[4] Liver International. (2013). Bacterially associated liver disease (BALD): A review of the current state. Retrieved from https://onlinelibrary.wiley.com/doi/full/10.1111/liv.12221

[5] World Health Organization. (2019). Essential medicines list. Retrieved from https://www.who.int/news-room/fact-sheets/detail/essential-medicines-list

[6] FDA. (2020). Off-label promotion. Retrieved from https://www.fda.gov/drugs/drug-innovation-off-label-promotion